Hospitals | September 15, 2021
Apollo Cancer Centres launch India’s first virtual duathlon
Proceeds raised from the duathlon will go towards cancer treatment of children identified by the hospital
Proceeds raised from the duathlon will go towards cancer treatment of children identified by the hospital
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
Crosscope and KFBIO join forces to lead digital transformation for pathology in India and emerging markets
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
According to WHO, over 1.5 million people died of TB in 2020
Subscribe To Our Newsletter & Stay Updated
